Sun Pharma's specialty product Ilumetri, indicated for psoriasis treatment, is now included in China's national reimbursement drug list, improving accessibility and affordability for patients.
New Delhi, Dec 13 (PTI) Sun Pharmaceutical Industries Ltd on Wednesday said its specialty product Ilumetri has been included in category B of China's national reimbursement drug list.
Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The inclusion of Ilumetri (Tildrakizumab) in China's national reimbursement drug list will be officially implemented from January 1, 2024, Sun Pharmaceutical Industries said in a regulatory filing.
In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings Ltd (CMS), for the Greater China market.
Ilumetri was approved for marketing in China in May 2023, it added.
"The inclusion of Ilumetri in category B of the national reimbursement drug list will further improve the accessibility and affordability of the innovative drug to benefit more patients," it added.
Rediff.com » Market News » Sun Pharma's Ilumetri Added to China Reimbursement Drug List
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback